Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in ...

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) have earned an average recommendation of “Buy” from the ...

Scotiabank analyst Greg Harrison maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $40.00.

KLP Kapitalforvaltning AS purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) in the fourth ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands against other best gene-editing ...

Beam Therapeutics Inc.’s BEAM share price has dipped by 11.15%, which has investors questioning if this is right time to buy.

Beam Therapeutics BEAM has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives ...

The field of gene editing recently got a major boost from Massachusetts-based Beam Therapeutics, and the company’s Durham ...

Beam Therapeutics (BEAM) presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin ...

Beam Therapeutics specializes in developing base-edited therapies for rare diseases and cancers. The company’s proprietary base editing platform allows for precise genetic modifications without ...

Still, BEAM-302 has innovative in vivo base editing technology that could potentially offer a one-time curative therapy for patients suffering from AATD. BEAM has a long cash runway, and its ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Beam Therapeutics Inc (Symbol: BEAM) entered into oversold territory, hitting an RSI ...